By HANA KAHLEOVA

Tuesday is World Osteoporosis Day, and one number deserves more attention than it gets: one in two women over 50 will break a bone because of osteoporosis. Bone loss speeds up as estrogen falls during menopause. Yet in the rush to treat midlife weight gain with the newest drugs, bones rarely come up.

I think of a patient who sat down and named the drug before she said anything else. She was in her early 50s, and she wanted a GLP-1, the weekly injection everyone seems to be on now. She had gained weight around her middle that nothing would touch, and she had not slept through the night in months. Two or three times a night she woke up soaked, kicked off the covers and lay awake. Two of her friends had started the drug that spring. She expected a prescription, not a conversation.

She is a composite of women I have treated, but her request is common. About one in five adults ages 50 to 64 have taken a GLP-1 drug, the highest share of any age group. Many are women looking for relief from the weight gain and broken sleep of the menopause transition.

They have good reason to want something that works. For generations, women’s menopause symptoms were minimized or left for them to endure. A drug that finally does something can feel like overdue respect. In a 15-minute visit, it is also the fastest thing a doctor can offer. That is not an unreasonable choice. The question is whether it should be the first one.

What changed my answer for this patient was a line already in her chart. A bone density scan the year before had shown osteopenia, the thinning that comes before osteoporosis. It had earned a note to keep an eye on it and then dropped out of the conversation, as these findings so often do.

Here is why it mattered. The weight people lose on GLP-1 drugs is not all fat. Across clinical trials of these medications, roughly a quarter of the weight lost was lean mass. In one retrospective study of patients taking semaglutide or tirzepatide, bone density at the hip fell by nearly 3% over about three years. For a woman already losing bone as estrogen declines, rapid weight loss lands on top of an existing deficit. And about half of patients stop semaglutide within a year, often regaining weight, so some pay that cost without keeping the benefit.